Call for papers - Real world evidence studies with antivirals for SARS-CoV-2

Guest Editors

Salvatore Rotundo, MD, Magna Graecia University, Italy
Daiki Wada, MD, PhD, Kansai Medical University, Japan

Submission Status: Open | Submission Deadline: 30 June 2025

BMC Infectious Diseases is calling for submissions to our Collection on Real world evidence studies with antivirals for SARS-CoV-2. We invite researchers to submit studies that utilize real world evidence to evaluate antiviral treatments for SARS-CoV-2. We welcome contributions that analyze health records, registries, and retrospective studies to enhance our understanding of treatment effectiveness and safety in diverse populations. By showcasing this research, we aim to inform clinical practices and public health strategies in the ongoing fight against COVID-19.

New Content Item This Collection supports and amplifies research related to SDG 3: Good Health and Well-being.

Submit to Collection

Meet the Guest Editors

Back to top

Salvatore Rotundo, MD, Magna Graecia University, Italy

Dr Salvatore Rotundo graduated in Medicine and Surgery with honors from the Magna Graecia University of Catanzaro in 2018. He is currently pursuing specialist training in Infectious Diseases at the same institution. His research focuses on infectious diseases, particularly COVID-19 and tuberculosis. Dr Rotundo has authored several papers in indexed journals and conducted peer reviews for prominent scientific journals including BMC Infectious Diseases and Scientific Reports. He is a member of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) and the Italian Society of Infectious and Tropical Diseases (SIMIT).

Daiki Wada, MD, PhD, Kansai Medical University, Japan

Dr Daiki Wada graduated from Osaka University School of Medicine in 2005. In 2009, he became a staff member at the Emergency and Critical Care Center of Osaka General Medical Center. In 2015, he obtained Doctor of Philosophy degree from Osaka University School of Medicine. Currently, Dr Wada is Senior Lecturer at Department of Emergency and Critical Care Medicine of Kansai Medical University General Medical Center. He has worked on the front line of COVID-19 and COVID-19 intensive care management at the same Institute since the beginning of the COVID-19 pandemic. His research interest focuses on the analysis about drug resistance mutation in immunocompromised COVID-19 patients. Dr Wada has published in peer-reviewed journals, authored and co-authored several abstracts, presented his research at national meetings, and mentored several trainees.

About the Collection

BMC Infectious Diseases is calling for submissions to our Collection on Real world evidence studies with antivirals for SARS-CoV-2. The emergence of SARS-CoV-2 has necessitated the rapid development and deployment of antiviral treatments to combat COVID-19. Real world evidence studies play a crucial role in understanding the effectiveness and safety of these antiviral therapies in diverse populations and clinical settings. By analyzing data from health records, registries, and retrospective studies, researchers can provide insights into how these treatments perform outside of controlled clinical trials.

Advancing our collective understanding of antiviral treatments for SARS-CoV-2 is essential for optimizing therapeutic strategies and improving public health responses. Significant progress has been made in identifying effective antiviral agents and understanding their mechanisms of action. Furthermore, real world evidence has highlighted variations in treatment efficacy across different demographics and comorbidities, underscoring the need for personalized treatment approaches. Continued research in this area will help refine treatment protocols and inform public health policies, ultimately enhancing patient care and outcomes.

This Collection aims to gather high-quality research dedicated to the real world application of antiviral treatments for SARS-CoV-2. Our focus is on studies that utilize real world data to assess the effectiveness, safety, and long-term outcomes of these antiviral interventions. We are particularly interested in studies that leverage retrospective data, real world evidence, and robust analyses of health records and registries to provide insights into the effectiveness, safety, and long-term outcomes of antiviral therapies for COVID-19. We welcome submissions that explore a wide range of topics, including but not limited to:

Comparative effectiveness of antiviral agents in different patient subgroups
Retrospective analyses of health records to evaluate treatment outcomes
The impact of antiviral therapy on long-term COVID-19 sequelae in real world populations
Drug resistance mutations and treatment strategies in patients with immunocompromised COVID-19
Utilization of real world data to inform treatment guidelines and public health strategies
Safety profiles of antivirals in populations underrepresented in clinical trials

This Collection supports and amplifies research related to SDG 3: Good Health and Well-being.

There are currently no articles in this collection.

Submission Guidelines

Back to top

This Collection welcomes submission of original Research Articles. Should you wish to submit a different article type, please read our submission guidelines to confirm that type is accepted by the journal. Articles for this Collection should be submitted via our submission system, Snapp. During the submission process you will be asked whether you are submitting to a Collection, please select "Real world evidence studies with antivirals for SARS-CoV-2" from the dropdown menu.

Articles will undergo the journal’s standard peer-review process and are subject to all of the journal’s standard policies. Articles will be added to the Collection as they are published.

The Editors have no competing interests with the submissions which they handle through the peer review process. The peer review of any submissions for which the Editors have competing interests is handled by another Editorial Board Member who has no competing interests.